Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?

ISRN Oncology
doi 10.1155/2014/596483
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Knockdown of Ribonucleotide Reductase Regulatory Subunit M2 Increases the Drug Sensitivity of Chronic Myeloid Leukemia to Imatinib‑based Therapy

Oncology Reports
MedicineCancer ResearchOncology
2019English

Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy

Experimental Oncology
Cancer ResearchOncology
2015English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

PLoS ONE
Multidisciplinary
2015English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy